Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | TOP2A | P11388 | 6/20 | 0.42 |
| ▸ | TOP2B | Q02880 | 6/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9097293 | 1.00 | DPP4 (0.47) | DPP4KEAP1NFE2L2CHRM2ALDH1A1 | |
| SCHEMBL9014149 | 1.00 | DPP4 (0.47) | DPP4KEAP1NFE2L2CHRM2ALDH1A1 | |
| SCHEMBL4747719 | 0.86 | TOP2A (0.47) | DPP4CHRM2ALDH1A1TOP2ATOP2B | |
| SCHEMBL9283675 | 0.86 | DPP4 (0.44) | DPP4CHRM2ALDH1A1POLBCHRM1 | |
| SCHEMBL500472 | 0.86 | DPP4 (0.57) | DPP4CHRM2ALDH1A1POLBCHRM1 | |
| SCHEMBL9233498 | 0.85 | DPP4 (0.35) | DPP4KEAP1NFE2L2CHRM2ALDH1A1 | |
| SCHEMBL9234525 | 0.85 | DPP4 (0.35) | DPP4KEAP1NFE2L2CHRM2ALDH1A1 | |
| SCHEMBL13483607 | 0.84 | KMT2A (0.43) | ALDH1A1POLBKMT2ALMNA | |
| SCHEMBL27789261 | 0.83 | DPP4 (0.52) | DPP4CHRM2ALDH1A1POLBCHRM1 | |
| SCHEMBL27344629 | 0.83 | DPP4 (0.48) | DPP4KEAP1NFE2L2CHRM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1666477-B1 | 7-(4-SUBSTITUTED 3- CYCLOPROPYLAMINOMETHYL-1- PYRROLIDINYL) Q UINOLONECARBOXYLIC ACID DERIVATIVE | KYORIN SEIYAKU KK (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-8106072-B2 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090176824-A1 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative technical field | ASAHINA YOSHIKAZU | 2009-07-09 | — | — | US | disclosed |
| US-7514451-B2 | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-07 | — | — | US | disclosed |
| EP-1304329-B1 | Pyridonecarboxylic acid derivatives and their use as antibacterial agents | DAIICHI SANKYO CO LTD (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1304329-B1 | Pyridonecarboxylic acid derivatives and their use as antibacterial agents | DAIICHI SANKYO CO LTD (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-20060281779-A1 | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| EP-1666477-A1 | 7-(4-SUBSTITUTED 3- CYCLOPROPYLAMINOMETHYL-1- PYRROLIDINYL) Q UINOLONECARBOXYLIC ACID DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-1304329-A2 | Pyridonecarboxylic acid derivatives and their use as antibacterial agents | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-23 | — | — | EP | disclosed |
| EP-0807630-A1 | HETEROCYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
| US-5545642-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-08-13 | — | — | US | disclosed |
| WO-1996001262-A1 | NOVEL QUINOLINE COMPOUND AND PROCESS FOR PREPARATION THEREOF | HANMI PHARMACEUTICAL CO., LTD. (KR) | 1996-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176824-A1 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative technical field | CLPP, PRSS1, FOSB | DPP4 496/4885KEAP1 2249/4885NFE2L2 2832/4885 |
| US-20060281779-A1 | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative | RPS27L, RPS7, RPSA | DPP4 367/4885KEAP1 1546/4885NFE2L2 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.